BC
ADPT icon

Brookfield Corp’s Adaptive Biotechnologies ADPT Stock Holding History

Brookfield Corp’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-192,258
Closed -$1.55M – 613
2022
Q2 		$1.55M Buy
+192,258
New +$1.69M 0.01% 451
2020
Q4 		– Sell
-49,774
Closed -$2.42M – 431
2020
Q3 		$2.42M Buy
+49,774
New +$2.09M 0.01% 218

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brookfield Corp's ADPT Position: Q3 2022 in Review

Brookfield Corp sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 192,258 shares — an estimated $1.55M sold.

Brookfield Corp first reported a position in ADPT in Q3 2020 and held it in 2 quarters. The position peaked at $2.42M in Q3 2020. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

  • Brookfield Corp reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Brookfield Corp sold 192,258 Adaptive Biotechnologies shares in Q3 2022, an estimated $1.55M.
  • Brookfield Corp first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 2 quarters.
  • Brookfield Corp's Adaptive Biotechnologies position peaked at $2.42M in Q3 2020.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.